Home > News > Lonnie Bookbinder Selected as CEO of SpeciGen
April 26th, 2006
Lonnie Bookbinder Selected as CEO of SpeciGen
Abstract:
SpeciGen announced today the appointment of Lonnie Bookbinder, MBA, Ph.D., of Corvallis Montana, as Chief Executive Officer. Dr. Bookbinder is the first CEO of SpeciGen and brings over 35 years of bio-pharmaceutical industry and executive experience to SpeciGen, an early stage drug development company. SpeciGen is an early stage developmental biotechnology company with a focus on drug delivery using nanotechnology.
Source:
pharmalive.com
Bookmark:
SpeciGen
Nanomedicine
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Appointments/Promotions/New hires/Resignations/Deaths
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
SEMATECH Names William R. Rozich Chairman of the Board June 13th, 2013
David Neuschuler Joins RASIRC to Manage Engineering June 3rd, 2013
Asylum Research Announces Ben Ohler as AFM Business Manager May 29th, 2013